Fluorescein sodium is a disclosing agent with molecular formula C20H10Na2O5, molecular weight 376.28, and chemical structure:
Spiro[isobenzofuran-1(3H), 9'-[9H]xanthene]-3-one, 3'6'-dihydroxy, Disodium salt
Benoxinate Hydrochloride is an anesthetic agent with molecular formula C17H28N2O3•HCl, molecular weight 344.88, and chemical structure:
Chemical Name: Benzoic acid, 4-amino-3-butoxyl-,2-(diethylamino) ethyl ester, monohydrochloride
Each mL contains:
Active: Benoxinate Hydrochloride 4 mg (0.4%), Fluorescein Sodium 2.5 mg (0.25%).
Preservative: Chlorobutanol 10 mg (1%).
Inactive: Povidone, Boric Acid, Sodium Hydroxide and/or Hydrochloric Acid (to adjust pH), Purified Water USP.
For procedures requiring a disclosing agent in combination with an anesthetic agent such as tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures.
DOSAGE AND ADMINISTRATION
Removal of foreign bodies and sutures, and for tonometry: 1 to 2 drops (in single instillations) in each eye before operating.
Deep ophthalmic anesthesia: 2 drops in each eye at 90 second intervals for 3 instillations.
NOTE: The use of an eye patch is recommended.
Fluress (fluorescein and benoxinate) is supplied as 5 mL contained in a 10 mL plastic bottle with a separate sterile dropper applicator. (NDC 17478-640-10)
Refrigerate at 2°-8°C (36°-46°F). User may store at room temperature for up to one month. Protect from light. Keep tightly closed.
Akorn Inc., Buffalo Grove, IL 60089. Rev 5/04
Occasional temporary stinging, burning and conjunctival redness have been reported after use of ocular anesthetics, as well as a rare severe, immediate-type, apparently hyperallergic corneal reaction with acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing or large areas of necrotic epithelium, corneal filaments and sometimes, iritis with descemetitis.
Allergic contact dermatitis with drying and fissuring of the fingertips has been reported.
No information provided.
NOT FOR INJECTION - FOR TOPICAL OPHTHALMIC USE ONLY
Prolonged use of a topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss.
Fluress® (Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP) should be used cautiously and sparingly in patients with known allergies, cardiac disease, or hyperthyroidism. The long-term toxicity is unknown; prolonged use may possibly delay wound healing. Although exceedingly rare with ophthalmic application of local anesthetics, systemic toxicity (manifested by central nervous system stimulation followed by depression) may occur.
Protection of the eye from irritating chemicals, foreign bodies and rubbing during the period of anesthesia is very important. Tonometers soaked in sterilizing or detergent solutions should be thoroughly rinsed with sterile distilled water prior to use. Patients should be advised to avoid touching the eye until the anesthesia has worn off.
Pregnancy Category C. Animal reproduction studies have not been conducted with Fluress® (fluorescein and benoxinate) . It is also not known whether Fluress® (fluorescein and benoxinate) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Fluress® (fluorescein and benoxinate) should be given to a pregnant woman only if clearly needed.
Caution should be exercised when Fluress® (fluorescein and benoxinate) is administered to a nursing woman.
The safety and effectiveness of this product in pediatric patients has not been established.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.